Does the media favor VERA or KYMR?

In the previous week, Kymera Therapeutics had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 2 mentions for Vera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat Vera Therapeutics' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VERA or ARWR?

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 6 mentions for Arrowhead Pharmaceuticals and 2 mentions for Vera Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.17 beat Vera Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to PTGX or VERA?

In the previous week, Protagonist Therapeutics and Protagonist Therapeutics both had 2 articles in the media. Protagonist Therapeutics' average media sentiment score of 0.83 beat Vera Therapeutics' score of 0.00 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VERA or IBRX?

In the previous week, ImmunityBio had 7 more articles in the media than Vera Therapeutics. MarketBeat recorded 9 mentions for ImmunityBio and 2 mentions for Vera Therapeutics. ImmunityBio's average media sentiment score of 0.67 beat Vera Therapeutics' score of 0.00 indicating that ImmunityBio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ImmunityBio 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TGTX or VERA?

In the previous week, TG Therapeutics had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 4 mentions for TG Therapeutics and 2 mentions for Vera Therapeutics. TG Therapeutics' average media sentiment score of 0.26 beat Vera Therapeutics' score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vera Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Vera Therapeutics (VERA) Competitors

$30.42 -0.57 (-1.84%)

Closing price 04:00 PM Eastern

Extended Trading

$30.51 +0.09 (+0.30%)

As of 06:33 PM Eastern

Compare

VERA vs. KYMR, ARWR, PTGX, IBRX, and TGTX

Should you buy Vera Therapeutics stock or one of its competitors? Vera Therapeutics's main competitors and comparable companies include Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), Protagonist Therapeutics (PTGX), ImmunityBio (IBRX), and TG Therapeutics (TGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vera Therapeutics compare to Kymera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

99.2% of Vera Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Vera Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the broader market.

Vera Therapeutics currently has a consensus price target of $80.15, suggesting a potential upside of 167.49%. Kymera Therapeutics has a consensus price target of $133.21, suggesting a potential upside of 22.17%. Given Vera Therapeutics' higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Kymera Therapeutics	1 Sell rating(s)	2 Hold rating(s)	22 Buy rating(s)	1 Strong Buy rating(s)	2.88

Vera Therapeutics has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -285.33%. Kymera Therapeutics' return on equity of -21.22% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Kymera Therapeutics	-285.33%	-21.22%	-19.21%

Vera Therapeutics has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Kymera Therapeutics	$39.21M	231.22	-$311.35M	-$3.24	N/A

In the previous week, Kymera Therapeutics had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 4 mentions for Kymera Therapeutics and 2 mentions for Vera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat Vera Therapeutics' score of 0.00 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Kymera Therapeutics beats Vera Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Vera Therapeutics compare to Arrowhead Pharmaceuticals?

Vera Therapeutics (NASDAQ:VERA) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Vera Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Arrowhead Pharmaceuticals has higher revenue and earnings than Vera Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
Arrowhead Pharmaceuticals	$829.45M	10.96	-$1.63M	-$2.25	N/A

Vera Therapeutics currently has a consensus price target of $80.15, suggesting a potential upside of 167.49%. Arrowhead Pharmaceuticals has a consensus price target of $98.31, suggesting a potential upside of 52.32%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Vera Therapeutics is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Vera Therapeutics has a net margin of 0.00% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

In the previous week, Arrowhead Pharmaceuticals had 4 more articles in the media than Vera Therapeutics. MarketBeat recorded 6 mentions for Arrowhead Pharmaceuticals and 2 mentions for Vera Therapeutics. Arrowhead Pharmaceuticals' average media sentiment score of 0.17 beat Vera Therapeutics' score of 0.00 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vera Therapeutics and Arrowhead Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Vera Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Protagonist Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 1.06, indicating that its stock price is 6% more volatile than the broader market.

In the previous week, Protagonist Therapeutics and Protagonist Therapeutics both had 2 articles in the media. Protagonist Therapeutics' average media sentiment score of 0.83 beat Vera Therapeutics' score of 0.00 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Protagonist Therapeutics has a net margin of 29.40% compared to Vera Therapeutics' net margin of 0.00%. Protagonist Therapeutics' return on equity of 12.03% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	29.40%	12.03%	11.23%
Vera Therapeutics	N/A	-84.13%	-66.79%

Protagonist Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$46.02M	197.05	-$130.15M	$1.03	136.05
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

Protagonist Therapeutics currently has a consensus price target of $147.13, indicating a potential upside of 4.99%. Vera Therapeutics has a consensus price target of $80.15, indicating a potential upside of 167.49%. Given Vera Therapeutics' higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	0 Sell rating(s)	2 Hold rating(s)	16 Buy rating(s)	0 Strong Buy rating(s)	2.89
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by company insiders. Comparatively, 15.9% of Vera Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Protagonist Therapeutics beats Vera Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Vera Therapeutics compare to ImmunityBio?

Vera Therapeutics (NASDAQ:VERA) and ImmunityBio (NASDAQ:IBRX) are both healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

Vera Therapeutics has a net margin of 0.00% compared to ImmunityBio's net margin of -598.55%. ImmunityBio's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-84.13%	-66.79%
ImmunityBio	-598.55%	N/A	-51.65%

99.2% of Vera Therapeutics shares are owned by institutional investors. Comparatively, 8.6% of ImmunityBio shares are owned by institutional investors. 15.9% of Vera Therapeutics shares are owned by insiders. Comparatively, 66.1% of ImmunityBio shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vera Therapeutics has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, ImmunityBio has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

Vera Therapeutics currently has a consensus target price of $80.15, indicating a potential upside of 167.49%. ImmunityBio has a consensus target price of $14.20, indicating a potential upside of 38.35%. Given Vera Therapeutics' higher possible upside, equities research analysts clearly believe Vera Therapeutics is more favorable than ImmunityBio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86
ImmunityBio	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Vera Therapeutics has higher earnings, but lower revenue than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Vera Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A
ImmunityBio	$113.29M	96.02	-$351.40M	-$0.97	N/A

In the previous week, ImmunityBio had 7 more articles in the media than Vera Therapeutics. MarketBeat recorded 9 mentions for ImmunityBio and 2 mentions for Vera Therapeutics. ImmunityBio's average media sentiment score of 0.67 beat Vera Therapeutics' score of 0.00 indicating that ImmunityBio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmunityBio	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vera Therapeutics and ImmunityBio tied by winning 7 of the 14 factors compared between the two stocks.

How does Vera Therapeutics compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Vera Therapeutics (NASDAQ:VERA) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

TG Therapeutics has higher revenue and earnings than Vera Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.33	$447.18M	$2.74	19.59
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.86	N/A

In the previous week, TG Therapeutics had 2 more articles in the media than Vera Therapeutics. MarketBeat recorded 4 mentions for TG Therapeutics and 2 mentions for Vera Therapeutics. TG Therapeutics' average media sentiment score of 0.26 beat Vera Therapeutics' score of 0.00 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vera Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TG Therapeutics has a beta of 1.8, meaning that its stock price is 80% more volatile than the broader market. Comparatively, Vera Therapeutics has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

TG Therapeutics has a net margin of 55.22% compared to Vera Therapeutics' net margin of 0.00%. TG Therapeutics' return on equity of 73.49% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Vera Therapeutics	N/A	-84.13%	-66.79%

58.6% of TG Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 8.9% of TG Therapeutics shares are owned by insiders. Comparatively, 15.9% of Vera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

TG Therapeutics presently has a consensus price target of $63.00, indicating a potential upside of 17.34%. Vera Therapeutics has a consensus price target of $80.15, indicating a potential upside of 167.49%. Given Vera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Vera Therapeutics is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.44
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

TG Therapeutics beats Vera Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Vera Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERA vs. The Competition

Export

Metric	Vera Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.19B	$3.84B	$7.10B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-5.19	12.99	274.61	26.05
Price / Sales	N/A	1,288.54	601.02	89.39
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	3.59	16.63	10.92	6.31
Net Income	-$299.61M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-6.52%	-3.06%	-2.11%	-1.67%
1 Month Performance	-14.69%	-10.76%	-6.34%	-3.94%
1 Year Performance	4.21%	21.10%	8.81%	2.77%

Vera Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERA Vera Therapeutics	3.0728 of 5 stars	$30.42 -1.8%	$80.15 +163.5%	+7.6%	$2.19B	N/A	N/A	361
KYMR Kymera Therapeutics	2.1363 of 5 stars	$112.00 +0.0%	$133.21 +18.9%	+101.5%	$9.31B	$39.21M	N/A	273	Insider Trade
ARWR Arrowhead Pharmaceuticals	2.9419 of 5 stars	$65.46 -0.7%	$98.31 +50.2%	+85.1%	$9.29B	$829.45M	N/A	711
PTGX Protagonist Therapeutics	1.6418 of 5 stars	$142.44 +0.4%	$147.13 +3.3%	+117.5%	$9.18B	$46.02M	138.29	141	News Coverage Insider Trade
IBRX ImmunityBio	2.8331 of 5 stars	$8.51 +0.8%	$14.20 +66.9%	+274.2%	$8.95B	$113.29M	N/A	691

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERA) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vera Therapeutics (VERA) Competitors

VERA vs. KYMR, ARWR, PTGX, IBRX, and TGTX

How does Vera Therapeutics compare to Kymera Therapeutics?

Summary

How does Vera Therapeutics compare to Arrowhead Pharmaceuticals?

Summary

How does Vera Therapeutics compare to Protagonist Therapeutics?

Summary

How does Vera Therapeutics compare to ImmunityBio?

Summary

How does Vera Therapeutics compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vera Therapeutics (VERA) Competitors

VERA vs. KYMR, ARWR, PTGX, IBRX, and TGTX

How does Vera Therapeutics compare to Kymera Therapeutics?

Do institutionals & insiders hold more shares of VERA or KYMR?

Which has more risk and volatility, VERA or KYMR?

Do analysts recommend VERA or KYMR?

Is VERA or KYMR more profitable?

Which has higher earnings & valuation, VERA or KYMR?

Does the media favor VERA or KYMR?

Summary

How does Vera Therapeutics compare to Arrowhead Pharmaceuticals?

Which has more risk and volatility, VERA or ARWR?

Which has higher earnings and valuation, VERA or ARWR?

Do analysts rate VERA or ARWR?

Do institutionals and insiders hold more shares of VERA or ARWR?

Is VERA or ARWR more profitable?

Does the media favor VERA or ARWR?

Summary

How does Vera Therapeutics compare to Protagonist Therapeutics?

Which has more volatility and risk, PTGX or VERA?

Does the media refer more to PTGX or VERA?

Is PTGX or VERA more profitable?

Which has preferable earnings & valuation, PTGX or VERA?

Do analysts prefer PTGX or VERA?

Do insiders and institutionals have more ownership in PTGX or VERA?

Summary

How does Vera Therapeutics compare to ImmunityBio?

Is VERA or IBRX more profitable?

Do institutionals & insiders believe in VERA or IBRX?

Which has more risk & volatility, VERA or IBRX?

Do analysts rate VERA or IBRX?

Which has better valuation and earnings, VERA or IBRX?

Does the media favor VERA or IBRX?

Summary

How does Vera Therapeutics compare to TG Therapeutics?

Which has preferable valuation & earnings, TGTX or VERA?

Does the media favor TGTX or VERA?

Which has more risk and volatility, TGTX or VERA?

Is TGTX or VERA more profitable?

Do insiders and institutionals believe in TGTX or VERA?

Do analysts rate TGTX or VERA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERA vs. The Competition

Vera Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools